Abcam (ABCZF) Debt-to-Asset : 0.21 (As of Jun. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Abcam Debt-to-Asset?

Abcam's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $161.0 Mil. Abcam's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $113.0 Mil. Abcam's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was $1,296.8 Mil. Abcam's debt to asset for the quarter that ended in Jun. 2023 was 0.21.

Abcam Debt-to-Asset Historical Data

The historical data trend for Abcam's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abcam Debt-to-Asset Chart

Abcam Annual Data

Trend

Jun12

Jun13

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.29

0.21

Abcam Semi-Annual Data
	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Jun22	Dec22	Jun23
Debt-to-Asset	Get a 7-Day Free Trial															0.14	0.13	0.22	0.21	0.21

Competitive Comparison of Abcam's Debt-to-Asset

For the Biotechnology subindustry, Abcam's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abcam's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abcam's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Abcam's Debt-to-Asset falls into.

Abcam Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Abcam's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(156.029	+	116.687)	/	1286.967
	=	0.21

Abcam's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(160.985	+	113.005)	/	1296.843
	=	0.21

Abcam (OTCPK:ABCZF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Abcam Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Abcam's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Abcam (ABCZF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abcam PLC (OTCPK:ABCZF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Discovery Drive, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AX

Website

https://www.abcam.com

Abcam PLC is a biotechnology company that develops and provides antibodies to life science research and clinical communities. The company's products allow research into the role of signaling and regulatory molecules and proteins in biological pathways. Such research ultimately leads to treatments for diseases such as cancer and immune deficiency disorders. Abcam's focused on broadening its product range, improving speed to market, and accessing underpenetrated consumer groups in its markets. The company also selectively pursues partnerships and acquisitions.